Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  12/18/2019
 
Trade Name:  Aralzo
 
Generic Name or Proper Name (*):  tazarotene
 
Indications Studied:  Acne
 
Label Changes Summary:  *Safety and effectiveness for the topical treatment of acne vulgaris have been established in pediatric patients age 9 years and older based on evidence from two multicenter, randomized, double-blind, parallel-group, vehicle-controlled, 12-week clinical trials and an open-label pharmacokinetic study. *A total of 300 pediatric subjects aged 9 to less than 17 years received Arazlo in the clinical studies. *Safety and effectiveness in pediatric patients below the age of 9 years have not been established. *New dosage form.
 
PREA(P):  P
 
Sponsor:  Bausch Health US, LLC
 
NNPS:  FALSE
 
Therapeutic Category:  Antiacne, topical
 
-
-